Clin2
NCT03370406Possibly a fitRecruiting

Test cream and injection treatment for skin squamous cell cancer

Carcinoma, Squamous Cell

Treatments studied

Part of Cancer clinical trials.

This early-phase study tests whether combining an injection into the skin lesion with a topical cream can treat squamous cell skin cancer. It may help shrink the cancer and improve control in people whose tumor is in the lower legs or feet.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have biopsy-confirmed squamous cell skin cancer (SCC) on your lower leg (knee and below), measuring between 1 and 2 cm.
  • You must be at least 18 years old and able to sign informed consent.
  • You should be healthy enough for study treatment, with an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
  • You cannot be taking any other study drug or device at the same time.
  • You cannot have cancer that has spread to lymph nodes or other parts of the body.
  • If you can become pregnant, you must have a negative pregnancy test before treatment and use effective birth control during the study and for 120 days after the last dose. If you are not past childbearing potential or are not surgically sterile, you also must avoid pregnancy throughout this period.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05377905Recruiting· Phase 1/Phase 2
Microneedle skin treatment plus doxorubicin for skin cancer

This early-phase study tests whether delivering chemotherapy through tiny skin needles (microneedles) can shrink or control cutaneous squamous cell cancer (cSCC) that can be surgically treated. Because it’s Phase 1/2, the main goals are to check safety and find the best way to deliver the treatment.

Pittsburgh, Pennsylvania
NCT05381597Recruiting· Phase 2/Phase 3
Skin cream treatment for small early non-melanoma skin cancers

This study tests whether 5-fluorouracil and calcipotriene (medicines used on the skin) can treat certain small, early skin cancers or pre-cancers without surgery. It’s for specific types and locations of lesions and aims to see how well the treatment works and how safe it is.

Boston, Massachusetts
NCT06782399Enrolling by invitation· Early Phase 1
Drug screening for skin squamous cell cancer lesions

This trial tests a device placed on skin cancer lesions to see which drugs might work best. It is for people with visible squamous cell carcinoma on the skin, including lesions that have come back after radiation.

Boston, Massachusetts
NCT06418724Not yet recruiting· Phase 2
Immunotherapy and targeted therapy before surgery for advanced skin cancer

This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (EGFR inhibitor)—given before surgery for locally advanced squamous cell skin cancer. The goal is to shrink the tumor enough to make surgery safer and more effective.

NCT05085496Recruiting· Phase 1
Radiation plus atezolizumab for advanced skin cancer

This Phase 1 trial studies adding atezolizumab (an immune therapy) to radiation for people with hard-to-remove or borderline-resectable cutaneous squamous cell carcinoma (cSCC). The goal is to see whether this combination can better control the cancer and whether the treatment is safe.

Duarte, California
NCT06499415Recruiting· Phase 4
Combination cream vs standard cream for precancerous skin spots

This trial tests if adding calcipotriol to a standard chemotherapy cream (5-fluorouracil) works better than the standard cream alone for treating actinic keratosis (precancerous sun-damaged skin spots). You may qualify if you have at least four spots on your face, scalp, neck, chest, or arms.

Heerlen, Limburg

Hear when a new Carcinoma, Squamous Cell trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.